Home :: Companies :: Vertex Pharmaceuticals

Latest Vertex Pharmaceuticals News

GSK and Vertex Pharmaceuticals Announce Presentation of Data ... - PR Newswire (press release)

-- Positive Data Presented at 45th Annual ICAAC -- CAMBRIDGE, Mass., Dec. 16 /PRNewswire-FirstCall/ -- GlaxoSmithKline (GSK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) presented positive results today from a study evaluating the safety, tolerability and antiviral activity of the investigational HIV-1 protease inhibitor (PI), brecanavir* (formerly known as GW640385 or VX-385)(1). These data were presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held in Washington DC. Interim findings following 24 weeks of dosing demonstrated potent antiviral activity for brecanavir in both PI-sensitive and PI-resistant HIV-infected Adult.. "These results support the ongoing development program for brecanavir, which is anticipated to enter Phase III development in 2006," said Lynn Marks, MD, Senior Vice President of the Infectious Disease Medicines Development Centre at GSK. "If approved, brecanavir May be useful in treating patients infected with strains of HIV that have become resistant to multiple protease inhibitors, and its clinical advancement underscores GSK's commitment to developing new anti-HIV drugs." Clinical Data on Brecanavir Brecanavir is an HIV protease inhibitor in Phase IIb clinical development. Brecanavir has received fast track designation from the U.S. Food and Drug Administration and is being developed by GSK as part of a collaboration with Vertex - More available

Vertex Pharmaceuticals

No Ebay Marketplace Listings Found